Skip to main content
OpenTrials
Completed

NCT Number: NCT05918484

Usefulness of Continuous Glucose Monitoring in MODY Diagnosis

Observational study about usefulness of intermittently scanned continuous glucose monitoring (isCGM) in the diagnosis of maturity-onset of the young (MODY) patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Albacete University Hospital, Albacete, Spain

Loading trial locations.

About this study

Cross-sectional retrospective analysis of all patients with type 1 diabetes (T1D) in Castilla-La Mancha (south-central Spanish region) using intermittently scanned continuous glucose monitoring (isCGM). This study aimed to asses the usefulness of isCGM in the diagnosis of MODY patients that were previously wrongly diagnosed as T1D patients.

The following glycometrics were taking into account as MODY predictors: time in range (70-180 mg/dL >70%, Glucose Management Index <7% y Coefficient of variation <36%. Patient´s clinical records of subjects meeting these glycometric criteria were reviewed for clinical suspicious of MODY (diagnosis before 35 years of age, first-degree family history of diabetes, negative pancreatic autoimmunity, preserved pancreatic beta cell function. Those patients meeting isCGM and clinical suspicious criteria were offered a diagnostic test for MODY.

The relationship between the qualitative outcome variable (MODY presence) and the quantitative variables will be performed using Student's t-test and ANOVA in situations of good fit with normality, and the Mann Whitney U and Kruskal Wallis when there is not a good fit with normality, and the Mann Whitney U and Kruskal Wallis when there is not.A P value < 0.05 was considered statistically significant.

The protocol was approved by the reference Castilla-La Mancha Public Health Institute Ethic Committee.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of T1D.
  • Age equal or higher than 18 years old.
  • In treatment with isCGM system.
  • Active data in Libreview.
  • isCGM use >70% of the possible time of use (isCGM data quality criteria).
  • Time in range >70%, glucose management index <7% and coefficiente of variation <36% in the last 14 days glucometric recording.

Exclusion criteria

  • Not receiving treatment with isCGM.
  • Diagnosis of T1D in the last three years.
  • Gestation in progress or programmed pregnancy.

Treatment and study plan

Intermittenly scanned continuous glucose monitoring

Device

Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:

  • Time in range 70-180 mg/L >70%
  • Glycemic management index <7%
  • Coefficient of variation <36%

MODY genetic diagnostic test

Other

Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:

  • diagnosis before 35 years of age
  • first-degree family history of diabetes.
  • negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)
  • preserved pancreatic beta cell function defined as C-peptide > 0.2 ng/mL in the presence of plasma glycemia >140 mg/dL).

Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test.

Primary outcomes

  1. Positive predictive value

    Time frame: 14 days

    Positive predictive value of the combination of the glucometric variables TIR>70%, GMI <7% and CV <36% in the diagnosis of MODY. Units % (min 0, max 100)

  2. Negative predictive value

    Time frame: 14 days

    Negative predictive value of the combination of the glucometric variables TIR>70%, GMI <7% and CV <36% in the diagnosis of MODY. Units % (min 0, max 100)

  3. Sensitive

    Time frame: 14 days

    Sensitive of the combination of the glucometric variables TIR>70%, GMI <7% and CV <36% in the diagnosis of MODY. Units % (min 0, max 100)

  4. Specificity

    Time frame: 14 days

    Specificity of the combination of the glucometric variables TIR>70%, GMI <7% and CV <36% in the diagnosis of MODY. Units % (min 0, max 100)

Secondary outcomes

  1. Percetage of wrongly diagnosed type 1 diabetes patients

    Time frame: 14 days

    To assess the percentage of MODY patients with misdiagnosis of DM1. Units % (min 0, max 100)

  2. Time in range of interstitial glucose in MODY patients

    Time frame: 14 days

    To assess the percetage of time in range (70-180 mg/dL, 3.9-10 mmol/L) of interstitial glucose in patients finally diagnosed as MODY. Units % (min 0, max 100)

  3. Time above range of interstitial glucose in MODY patients.

    Time frame: 14 days

    To assess the percentage of time above range (>180 mg/dL, >10 mmol/L) of patients finally diagnosed as MODY. Units % (min 0, max 100)

  4. Time beloww range of interstitial glucose in MODY patients.

    Time frame: 14 days

    To assess the percentage of time bellow range (<70 mg/dL, <3.9 mmol/L) of patients finally diagnosed as MODY. Units % (min 0, max 100)

  5. Coefficient of variation of interstitial glucose in MODY patients.

    Time frame: 14 days

    To assess the coefficient of variations of patients finally diagnosed as MODY. Units % (min 0, max 100)

  6. isCGM daily scan frequency in MODY patients

    Time frame: 14 days

    To analyze the use of iCGM in patients finally diagnosed as MODY through daily frequency of scanning (number daily scans, min 0-max 100).

  7. Percentage of iCGM in MODY patients

    Time frame: 14 days

    To analyze the percentage of iCGM use in patients finally diagnosed as MODY (% time in use, units %, mix 0- max 100).

Sponsors and collaborators

Lead sponsor

Castilla-La Mancha Health Service

Other

Registry information

Official study title

Usefulness of Intermittently Scanned Continuous Glucose Monitoring in the Diagnosis of Maturity-onset Diabetes of the Young (MODY) Patients

Acronym: UCMODY

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 26, 2023
Registry last updated
Feb 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.